English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNIBIB-funded researchers at Stanford University have created an artificial neural network that analyzes lung CT scans to provide information about lung cancer severity that can guide treatment options.
Tag: Lung Cancer
Monoclonal Antibody Restores T-Cell Ability to Kill Cancer
A new class of anticancer agents can restore the ability of cytotoxic T lymphocytes (CTLs) to infiltrate the tumor and kill target cells in patients with metastatic non-small cell lung cancer (mNSCLC).
Memorial Sloan Kettering Awards & Appointments
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
Scientists Discover that Nicotine Promotes Spread of Lung Cancer to the Brain
Among people who have the most common type of lung cancer, up to 40% develop metastatic brain tumors, with an average survival time of less than six months.
Continued nicotine use promotes brain tumors in lung cancer patients, Wake Forest study suggests
Researchers at Wake Forest School of Medicine have discovered that nicotine promotes the spread of lung cancer cells into the brain, where they can form deadly metastatic tumors. The study, which will be published June 4 in the Journal of Experimental Medicine (JEM), suggests that nicotine replacement therapies may not be suitable strategies for lung cancer patients attempting to quit smoking. In addition, the researchers show that the naturally occurring drug parthenolide blocks nicotine-induced brain metastasis in mice, suggesting a potential therapeutic option in humans.
Researchers Identify a Moving Target in Small Cell Lung Tumors
About 15 percent of lung cancers are classified as small cell lung cancer. Recent studies have indicated that four major subtypes of small cell lung cancer exist, yet approaches to tailor treatment of these subtypes have not yet become standard of care. Today in the journal Cancer Cell, scientists outline new findings about the origins of these lung cancer subtypes, paving the way for a new foundation to study this disease.
Study finds overwhelming support for smoke-free policies among Los Angeles tenants, landlords
Half of apartment dwellers in Los Angeles report having been exposed to unwanted secondhand smoke in their homes in the last year, and 9 in 10 of them say they favor policies banning smoking from their buildings, a new study by researchers at the Fielding School of Public Health’s UCLA Center for Health Policy Research reveals.
Study Shows Promise for Non-Small Cell Lung Cancer Patients Who Require New Treatment Options
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System. Early results appear promising in this phase 1/2 clinical trial of ADXS-503 being developed by Advaxis, Inc., a new type of cancer therapy which targets “hotspot” mutations that commonly occur in specific cancer types, both by itself and in combination with immunotherapy Keytruda® (pembrolizumab), which is commonly used to treat this type of lung cancer. Dr. Haigentz and colleagues published early results of this study in conjunction with ASCO 2020, the world’s premier scientific meeting for clinical research in oncology.
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
MSK: Cancer Isn’t Sheltering in Place
As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now – as the long-term toll of missed diagnoses and delayed treatments could be devastating for patients and their loved ones across the region and the country.
NCCN Foundation Awards Leading Young Investigators Advancing Cancer Research for Adults and Children
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
New CAP Guideline Improves Collection, Handling of Lung Specimens
The College of American Pathologists (CAP) released a new evidence- based guideline “Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies” to clarify procedures and methods to optimize test outcomes.
Variations in side effect reporting makes drug safety unclear
University of Colorado Cancer Center study of early-phase clinical trials finds variations in reporting of drug side effects, potentially obscuring safety.
Series of rare right-colon twists highlights need for doctor vigilance with new, targeted anti-cancer drugs
Study: with smaller clinical trials, it may be up to doctors to notice rare drug side effects
Uptake of Lung Cancer Screening May Depend on Making Testing Fast and Convenient
Value in Health announced today the publication of new research showing that uptake of lung cancer screening may depend on making testing fast and convenient.
Smoking Increases Risk for COVID-19 Complications—So It’s a Great Time to Quit
It is well known that smoking results in worse outcomes in people with pneumonia or influenza, and we are learning that smoking can pose significant risks in those with COVID-19.
First Test Using Immunotherapy Drug to Treat Advanced Lung Cancer Shows Benefit — And Future Promise
Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab can extend life with very few side effects in this patient population.
NUS researchers uncover hereditary mutation that drives aggressive head and neck, and lung cancers in Asian population
New research from the Cancer Science Institute of Singapore at the National University of Singapore revealed a genetic variant in a gene called MET that is responsible for more aggressive growth of head and neck, and lung cancers in Asian populations.
New therapeutic strategies proposed for some lung and kidney cancers
New therapeutic strategies proposed for some lung and kidney cancers. Study shows cancers with high levels of the SLC7A11 gene may respond to glucose transporter inhibitor treatment.
Moffitt Researchers Discover Novel Role of Specific Histone Deacetylase in Non-Small Cell Lung Cancer
Researchers at Moffitt Cancer Center are trying to identify alternative strategies to treat non-small cell lung cancer. (NSCLC) In a new article published online in Scientific Reports, they highlight how targeting the histone deacetylase HDAC11 may be a novel therapeutic strategy for NSCLC.
Those Living in Rural Areas, Uninsured or on Medicaid Less Likely to Receive Recommended Lung Cancer Treatment
Keck Medicine of USC study reveals that non-small cell lung cancer patients with pathologic N1 disease were less likely to receive chemotherapy if they lived in rural areas or were on Medicaid or uninsured.
For Every 50 Smokers – One Non-Smoker Dies from Secondhand Smoke Exposure
New data analysis could change smoking policies worldwide to protect non-smokers and reduce their risk
Researchers identify marker that may predict whether lung cancer likely to spread
Researchers at Tulane University have identified a protein on tumor-derived extracellular vesicles that indicates if a NSCLC tumor is likely to metastasize, according to a new study in Science Advances.
NCCN and AstraZeneca Announce Projects to Explore Quality Improvements in Lung Cancer
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced three research projects selected to receive funding to improve healthcare provider performance and/or healthcare quality, focusing on enhancing patient care and outcomes for people with NSCLC.
Dr. Donald Sullivan Receives ATS Foundation Research Program/American Lung Association Partner Grant
The ATS Foundation Research Program and the American Lung Association have awarded Donald Sullivan, MD, of Oregon Health & Science University a $100,000 Foundation Partner grant. The ATS Foundation Partner Grants provide crucial support to talented investigators from around the world, launching careers dedicated to scientific discovery and better patient care.
Baylor Scott & White’s Glenda Tanner Vasicek Cancer Treatment Center – Temple Announces Construction of New Radiation Oncology Facility
Baylor Scott & White Health’s Glenda Tanner Vasicek Cancer Treatment Center (VCTC) – Temple announces construction of a new radiation oncology facility that will benefit Central Texas patients being treated for cancer. With new radiation treatment equipment and more room for procedures, the facility will be able to treat up to 70 patients per day.
Yale Cancer Center Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).
Addition of Immunotherapy to Standard Treatment for Advanced Stage Non-Small Cell Lung Cancer is Safe and Tolerable as First-Line Therapy
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).
UCLA researchers discover new compound that promotes lung health
A molecule identified by UCLA researchers helps maintain a healthy balance of cells in airway and lung tissue. If the compound, so far only studied in isolated human and mouse cells, has the same effect in people, it may lead to new drugs to treat or prevent lung cancer.
Intratumoral heterogeneity may be responsible for chemotherapy resistance in patients with small cell lung cancer
A study at The University of Texas MD Anderson Cancer Center found that chemotherapy results in increased heterogeneity within small cell lung cancer, leading to the evolution of multiple resistance mechanisms.
Lung Cancer Screening Saves Lives!
Dr. Douglas E. Wood describes the findings from the NELSON Trial and what they mean for policy and program development for lung cancer early detection through CT screening.
36-year-old physician with stage 4 lung cancer offers inspiration
Morhaf Al Achkar is a 36-year-old family medicine physician at UW Medicine who has been living with stage 4 lung cancer for more than three years. Dr. Al Achkar never smoked but, like many with the disease, he has a…
Lung cancer screening decision aid delivered through tobacco quitlines improves informed decision-making
Researchers from The University of Texas MD Anderson Cancer Center have shown that a decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population and results in informed decisions about lung cancer screening.
Expert Available to Discuss NELSON Trial and Lung Cancer Screening
WHO: Douglas E. Wood, MD, from the University of Washington in Seattle, is a world-renowned surgeon in thoracic oncology. Dr. Wood is a national and international leader in the management of lung and esophageal cancer. He has used that expertise…
Physicians and Regulators Must Act on NELSON Study published in NEJM to Support Widespread Lung Cancer Screening
The Dutch-Belgian Randomized Lung Cancer Screening Trial, known as the NELSON trial (de Koning et al), published Jan. 29 in NEJM, reconfirms that screening high-risk patients greatly reduces lung cancer deaths. Regulators and physicians should act to ensure access to these lifesaving exams.
First-of-its-Kind Technology Lights Up Lung Cancer Cells, Helps Improve Patient Outcomes
A groundbreaking tumor-highlighting technology—OTL38—enhances the visualization of lung cancer tissue, providing surgeons with a significantly better chance of finding and removing more cancer than previously possible.
Multimodal Genomic Analyses Predict Response to Immunotherapy in Lung Cancer Patients
Researchers at Johns Hopkins Kimmel Cancer Center, the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine have developed an integrated genomic approach that potentially could help physicians predict which patients with nonsmall cell lung cancer will respond to therapy with immune checkpoint inhibitors.
Patient step counts predict lung cancer treatment outcomes, study finds
Numerous studies have shown that monitoring physical activity promotes better health – from reducing body mass index to watching for signs of hypertension, for example. A new study suggests step counters could play yet another role: predicting outcomes for people undergoing chemoradiation therapy for lung cancer.
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer.
Case Western Reserve researchers to lead Northeast Ohio initiative to prevent, detect and treat lung cancer in underserved communities
With a $2.75 million, three-year grant from the Bristol-Myers Squibb (BMS) Foundation, researchers from Case Western Reserve University will lead a community wide initiative to create and apply innovative methods to prevent and detect lung cancer in underserved residents in Northeast Ohio.
Researchers find protein promotes cancer, suppresses anti-tumor immunity
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes, TBK1, also can fuel cancer development and suppress immune response to the disease.
$2.3 Million in American Cancer Society Grants Awarded to Rutgers Cancer Institute Researchers
More than $2.3 million in Research Scholar Grants from the American Cancer Society have been awarded to three Rutgers Cancer Institute of New Jersey researchers to examine cell metabolism and tumor formation in forms of breast cancer, lung cancer and leukemia.
Surgery Provides ‘Oldest Old’ Lung Cancer Patients with Excellent 5-Year Survival
Many patients with early stage lung cancer who are age 90 years and older do not receive treatment; however, surgery in this nonagenarian population should be considered because it could significantly increase the chances for 5-year survival.
Lung Cancer in Women – UCLA Health Pulmonologist describes the signs & symptoms of this deadly disease
It’s Lung Cancer Awareness Month and there are few stories about women who are diagnosed with lung cancer. Here’s one story about a 42-year-old, non-smoking Mom of two who was surprised with a lung cancer diagnosis last Thanksgiving. The story also features tips from a UCLA pulmonologist on the signs and symptoms of lung cancer.
Smilow Cancer Hospital expert explains five things you need to know about Lung Cancer
Roy Herbst, M.D., Ph.D., chief of Medical Oncology at Smilow Cancer Hospital, has been researching lung cancer and treating patients with the disease for more than 25 years. He discusses the facts about lung cancer, ways to reduce your risk, and how new treatments are significantly extending life for patients.
November is Lung Cancer Awareness Month
Experts from the Rutgers Tobacco Dependence Program share more about the causes and risk factors for lung cancer, which include smoking. At focus is prevention, including tobacco cessation.
Black and Elderly Patients Less Likely to Receive Lung Cancer Treatments
Only about 6 in 10 lung cancer patients in the United States receive the minimal lung cancer treatments recommended by the National Comprehensive Cancer Network guidelines, according to new research published online in the Annals of the American Thoracic Society.
National Comprehensive Cancer Network Oncology Research Program Supports Clinical Trial for Lung Cancer
The National Comprehensive Cancer Network (NCCN®) Oncology Research Program (ORP) announces plans to support a phase II randomized trial for lung cancer patients with EGFR mutation or who have never smoked.